For­get the IPO, Il­lu­mi­na is near­ing a buy­out of $1.9B liq­uid biop­sy start­up Grail — re­port

5 years ago
Deals
R&D

News brief­ing: Top FDA of­fi­cial ex­its; Sun Ge­nomics clos­es $9.25M Se­ries A

5 years ago
News Briefing

Ex-Al­ler­gan CMO takes the helm at Lewis Cant­ley's metas­ta­sis-fo­cused biotech start­up

5 years ago
People

Metacrine, a Rich Hey­man biotech tar­get­ing NASH and oth­er liv­er dis­eases, rais­es $85M from IPO

5 years ago
Financing
R&D

Ver­sant teams up with Stan­ford gene edit­ing ex­perts on a $45M next-gen play — mar­ry­ing CRISPR and AAV to fix sick­le ...

5 years ago
Financing
Startups

Near­ly two years af­ter their nar­row PhI­II fail­ure, Or­p­hazyme gets speedy look at the FDA

5 years ago
R&D
FDA+

An­a­lysts are quick to pan Eli Lil­ly's puz­zling first cut of pos­i­tive clin­i­cal da­ta for its Covid-19 an­ti­body

5 years ago
R&D
Coronavirus

Covid-19 roundup: Warp Speed re­leas­es vac­cine dis­tri­b­u­tion plans, but leaves key ques­tions unan­swered

5 years ago
Coronavirus

Cyg­nal's Pearl Huang re­cruits for­mer Mer­ck col­league John Wag­n­er to re­al­ize broad ex­oneur­al vi­sion in the clin­ic

5 years ago
People

A month af­ter los­ing its lead pro­gram, Uni­ty Biotech­nol­o­gy cuts 30% of staff in re­struc­tur­ing

5 years ago
R&D
Pharma

Us­ing AI to se­quence fun­gi genomes for can­cer treat­ments, Hexa­gon Bio nets $47M in Se­ries A

5 years ago
Financing
R&D

NIH ‘very con­cerned’ about se­ri­ous side ef­fect in As­traZeneca's PhI­II Covid-19 tri­al

5 years ago
FDA+
Coronavirus

Crown jew­el in big Gilead buy­out lands break­through des­ig­na­tion for MDS

5 years ago
FDA+

Ex-Mod­er­na CFO Lorence Kim joins a new class of ven­ture part­ners jump­ing on board Third Rock

5 years ago
People

The cen­tral fig­ure in Nestlé's $2.6B Aim­mune buy­out? Covid-19

5 years ago
Deals
R&D

News brief­ing: Fre­quen­cy posts ex­tend­ed pos­i­tive re­sults for hear­ing loss pro­gram; Kiniksa earns ODD for GCA ...

5 years ago
News Briefing

Take­da opens cell ther­a­py man­u­fac­tur­ing fa­cil­i­ty — tucked right in its Boston R&D hub

5 years ago
Cell/Gene Tx

Pfiz­er ex­ecs con­fi­dent­ly tap their top 10 block­busters-to-be. But what are the chances of sur­viv­ing PhI­II, let alone ...

5 years ago
R&D

Covid-19 roundup: Ger­many pours near­ly $450M in­to BioN­Tech; As­traZeneca still has­n't re­sumed its vac­cine tri­al in the ...

5 years ago
Coronavirus

Fol­low­ing job cuts and R&D re­struc­tur­ing, mi­cro­cap mi­croR­NA play­er mi­Ra­gen brings in new CEO to right the ship

5 years ago
People

Akcea’s board man­aged to get Io­n­is to boost its buy­out bid a bit, but nev­er got close to a 2019 ac­qui­si­tion of­fer

5 years ago
Deals

Im­Check adds $7.1M to Se­ries B, boost­ing de­vel­op­ment of gam­ma delta T cell pro­grams

5 years ago
Financing

At­tempt­ing to bounce back af­ter mid-stage flop, Novus piv­ots to im­munol­o­gy with CD40L-fo­cused ac­qui­si­tion of Anelix­is

5 years ago
Deals

Mar­i­nus ex­ecs her­ald the re­birth of the one-drug biotech as a pos­i­tive PhI­II read­out ar­rives for a rare dis­ease

5 years ago
R&D
FDA+
First page Previous page 801802803804805806807 Next page Last page
A service from the Financial Times